Company Overview - Haemonetics Corporation provides blood management solutions globally, serving blood and plasma collectors, hospitals, and healthcare providers. The company's offerings include integrated devices, information management, and consulting services that enhance clinical outcomes across the blood supply chain [11]. Investment Insights - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [12]. - The stock has a Momentum Style Score of B, with shares increasing by 50.5% over the past four weeks, suggesting strong recent performance [12]. - For fiscal 2026, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising by $0.07 to $4.87 per share. The company has an average earnings surprise of +6% [12]. Conclusion - With a strong Zacks Rank and favorable Momentum and VGM Style Scores, Haemonetics is positioned as a noteworthy option for investors [13].